SARS-CoV-2 Drug Discovery Services
SARS-CoV-2 inhibitor screening is an essential part of COVID-19 preclinical drug discovery offered by Reaction Biology. As a CRO (contract research organization) we support the drug discovery community in the challenge to identify efficacious COVID-19 drugs with specific assays for SARS-CoV-2 drug testing with the goal to block virus entry and replication.
Our SARS-CoV-2 drug discovery services are available for pharmaceutical companies and medical researchers worldwide. Get in touch with the business development manager assigned to your country today.
Beside virus replication drugs are also developed to alleviate COVID-19 symptoms with a variety of targets that are well established for medical treatment:
|Target name||Target family||Assay format|
|ABL||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|AXL||Kinase||³³PanQinase, HotSpot, NanoBRET, Cellular Phosphorylation Assay, Recombinant Protein|
|BRD4||Reader Domain||AlphaScreen, TSA, ITC, MST, SPR|
|BTK||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|CDK4||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|CDK6||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|EGFR||Kinase||³³PanQinase, HotSpot, NanoBRET, Cellular Phosphorylation Assay, Recombinant Protein|
|JAK1||Kinase||³³PanQinase, HotSpot, Recombinant Protein|
|JAK2||Kinase||³³PanQinase, HotSpot, Recombinant Protein|
|JAK3||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|SYK||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|TYK2||Kinase||³³PanQinase, HotSpot, NanoBRET|
E Pairo-Castineira et al., Nature, 2020. Genetic mechanisms of critical illness in COVID-19.
Y Qiao et al., PNAS, 2020. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.
E Weisberg et al., Pharm Res., 2020. Repurposing of Kinase Inhibitors for Treatment of COVID-19.